Matrix metalloproteinases as biomarkers of disease: updates and new insights

References

1. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012;103:209–79.Search in Google Scholar

2. Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm 2013;2013:659282.10.1155/2013/659282Search in Google Scholar PubMed PubMed Central

3. Huxley-Jones J, Robertson DL, Boot-Handford RP. On the origins of the extracellular matrix in vertebrates. Matrix Biol 2007;26:2–11.10.1016/j.matbio.2006.09.008Search in Google Scholar PubMed

4. Amalinei C, Caruntu ID, Giusca SE, Balan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010;51:215–28.Search in Google Scholar

5. Galliera E, Banfi G, Corsi MM. Human bone disorders: pathological role and diagnostic potential of matrix metalloproteinases. Int J Biochem Cell Biol 2010;42:1590–3.10.1016/j.biocel.2010.06.015Search in Google Scholar PubMed

6. Galliera E, Randelli P, Dogliotti G, Dozio E, Colombini A, Lombardi G, et al. MM: Matrix metalloproteases MMP-2 and MMP-9: are they early biomarkers of bone remodelling and healing after arthroscopic acromioplasty? Injury 2010;41:1204–7.10.1016/j.injury.2010.09.024Search in Google Scholar PubMed

7. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346–59.10.1016/j.bcp.2007.07.004Search in Google Scholar PubMed PubMed Central

8. Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal Biochem 2008;374:56–63.10.1016/j.ab.2007.11.020Search in Google Scholar PubMed

9. Mannello F, Tonti GA, Tanus-Santos JE, Gerlach RF. Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators. Clin Chem 2007;53:1981–2.10.1373/clinchem.2007.090548Search in Google Scholar PubMed

10. Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, Cavalli RC, et al. Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 2009;47:888–91.10.1515/CCLM.2009.203Search in Google Scholar PubMed

11. Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35:1–10.10.1007/s12020-008-9114-6Search in Google Scholar PubMed PubMed Central

12. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358–73.10.1097/01.ASN.0000065640.77499.D7Search in Google Scholar

13. Santos JM, Tewari S, Lin JY, Kowluru RA. Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy. Biochem Biophys Res Commun 2013;438:760–4.10.1016/j.bbrc.2013.07.066Search in Google Scholar PubMed PubMed Central

14. Van Geest RJ, Klaassen I, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, et al. Vitreous TIMP-1 levels associate with neovascularization and TGF-beta2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy. J Cell Commun Signal 2013;7:1–9.10.1007/s12079-012-0178-ySearch in Google Scholar PubMed PubMed Central

15. Lewandowski KC, Banach E, Bienkiewicz M, Lewinski A. Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci 2011;7:294–303.10.5114/aoms.2011.22081Search in Google Scholar PubMed PubMed Central

16. Singh K, Agrawal NK, Gupta SK. A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int J Low Extrem Wounds 2013;12:199–204.10.1177/1534734613493289Search in Google Scholar PubMed

17. Loukovaara S, Robciuc A, Holopainen JM, Lehti K, Pessi T, Liinamaa J, et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 2013;91:531–9.10.1111/j.1755-3768.2012.02473.xSearch in Google Scholar PubMed

18. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013;2013:928315.10.1155/2013/928315Search in Google Scholar PubMed PubMed Central

19. Antoszewska M. Evaluation of the levels of metalloproteinsase-2 in patients with abdominal aneurysm and abdominal hernias. Pol Przegl Chir 2013;85:271–8.10.2478/pjs-2013-0041Search in Google Scholar PubMed

20. Berry E, Bosonea AM, Wang X, Fernandez-Patron C. Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease. J Vasc Res 2013;50:52–68.10.1159/000345240Search in Google Scholar PubMed

21. Lenglet S, Thomas A, Chaurand P, Galan K, Mach F, Montecucco F. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb Haemost 2012;107:409–16.10.1160/TH11-10-0717Search in Google Scholar PubMed

22. Silvello D, Narvaes LB, Albuquerque LC, Forgiarini LF, Meurer L, Martinelli NC, et al. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers 2014;19:49–55.10.3109/1354750X.2013.866165Search in Google Scholar PubMed

23. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012;413:656–62.10.1016/j.cca.2011.12.021Search in Google Scholar PubMed

24. Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets 2013;14:335–43.Search in Google Scholar

25. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008;41:875–80.10.1016/j.clinbiochem.2008.04.015Search in Google Scholar PubMed

26. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47:117–22.10.1097/01.fjc.0000196241.96759.71Search in Google Scholar PubMed

27. Bench TJ, Jeremias A, Brown DL. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol Res 2011;64:561–6.10.1016/j.phrs.2011.05.002Search in Google Scholar PubMed

28. Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K, et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2012;3:370–84.10.1002/emmm.201100145Search in Google Scholar PubMed PubMed Central

29. Muhl D, Nagy B, Woth G, Falusi B, Bogar L, Weber G, et al. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care 2011;26:550–5.10.1016/j.jcrc.2011.02.011Search in Google Scholar PubMed

30. Gaddnas FP, Sutinen MM, Koskela M, Tervahartiala T, Sorsa T, Salo TA, et al. Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis. Crit Care 2010;14:R49.10.1186/cc8938Search in Google Scholar PubMed PubMed Central

31. Teng L, Yu M, Li JM, Tang H, Yu J, Mo LH, et al. Matrix metalloproteinase-9 as new biomarkers of severity in multiple organ dysfunction syndrome caused by trauma and infection. Mol Cell Biochem 2012;360:271–7.10.1007/s11010-011-1066-0Search in Google Scholar PubMed

32. Romi F, Helgeland G, Gilhus NE. Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur Neurol 2012;67:121–8.10.1159/000334862Search in Google Scholar PubMed

33. Florczak-Rzepka M, Grond-Ginsbach C, Montaner J, Steiner T. Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: an update. Cerebrovasc Dis 2012;34:249–62.10.1159/000341686Search in Google Scholar PubMed

34. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2009;16:801–9.10.1177/1352458510370791Search in Google Scholar PubMed

35. Thorne M, Moore CS, Robertson GS. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol 2009;211:92–100.10.1016/j.jneuroim.2009.04.003Search in Google Scholar PubMed

36. Helgeland G, Petzold A, Luckman SP, Gilhus NE, Plant GT, Romi FR. Matrix metalloproteinases in myasthenia gravis. Eur Neurol 2011;65:53–8.10.1159/000322737Search in Google Scholar PubMed

37. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013;34:2041–51.10.1007/s13277-013-0842-8Search in Google Scholar PubMed

38. Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med 2011;15:1254–65.10.1111/j.1582-4934.2011.01302.xSearch in Google Scholar PubMed PubMed Central

39. Rucci N, Sanita P, Angelucci A. Roles of metalloproteases in metastatic niche. Curr Mol Med 2011;11:609–22.10.2174/156652411797536705Search in Google Scholar PubMed